Print this pageAbout Us
Fresenius Kabi at a glance
Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the U.S. market.
The company is focused on the therapy and care of critically and chronically ill patients in and outside the hospital.
Fresenius Kabi has more than 24,000 employees worldwide and a global network of around 55 sales organizations and more than 60 production sites and compounding centers. In 2011, Fresenius Kabi's sales were €3,964 million and the company's EBIT was €803 million.
Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE & Co. KGaA.
Key Figures
| € in millions |
2011 |
2010 |
Change |
| Sales |
3,964 |
3,672 |
8% |
| EBITDA |
955 |
893 |
7% |
| EBIT |
803 |
737 |
9% |
| Net Income* |
354 |
294 |
20% |
| Employees (Dec. 31) |
24,106 |
22,851 |
5% |
*Net income attributable to Fresenius Kabi AG.